{"nctId":"NCT01047839","briefTitle":"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries","startDateStruct":{"date":"2010-01"},"conditions":["Encephalitis"],"count":100,"armGroups":[{"label":">=2 months to <3 years","type":"EXPERIMENTAL","interventionNames":["Biological: IC51"]},{"label":">=3 to <12 years","type":"EXPERIMENTAL","interventionNames":["Biological: IC51"]},{"label":">=12 to <18 years","type":"EXPERIMENTAL","interventionNames":["Biological: IC51"]}],"interventions":[{"name":"IC51","otherNames":[]},{"name":"IC51","otherNames":[]},{"name":"IC51","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female healthy children and adolescents aged \\>=2 months to \\<18 years at the time of first vaccination\n* Written informed consent by the subject's legal representative(s), according to local requirements, and written informed assent of the subject, if applicable\n* Female subjects: either no childbearing potential or negative pregnancy test. For females after menarche willingness to practice a reliable method of contraception.\n* The subject is planning to travel to an area where JE is endemic after completion of the vaccination schedule. Exposure to JE should be avoided until 1 week after the second IC51 dose and subjects should return from travel to JE endemic areas before the Month 7 visit. The planned travel to JE endemic areas should not interfere with the study visits and can take place between Visit 2 + 7 days to Month 7.\n\nExclusion Criteria:\n\n* Clinical manifestation or history of any Flavivirus disease\n* Vaccination against JE (except within this protocol), Yellow fever, West Nile virus and Dengue at any time prior or during the study\n* History of immunodeficiency or immunosuppressive therapy\n* Known HIV, HBV or HCV infection\n* History of hypersensitivity reactions to other vaccines\n* Acute febrile infection at each visit during which the subject receives a vaccination\n* Active or passive immunization within 1 week before and 1 week after each IC51 vaccination.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination","description":"Rate of subjects with serious adverse events (SAEs) and medically attended AEs up to Day 56 after the first vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"20.7","spread":null},{"groupId":"OG002","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Month 7 After the First Vaccination","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With Solicited Local and Systemic aEs Assessed With a Subject Diary for 7 Consecutive Days After Each Vaccination","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"48.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"46.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"29.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"22.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With Unsolicited AEs up to Day 56 and up to Month 7 After the First Vaccination","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"43.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Subjects With Abnormal Laboratory Parameters up to Day 56 and up to Month 7 After the First Vaccination","description":"Laboratory parameters were assessed at the Day 28, Day 56 and Month 7 visit. Endpoint reflects abnormal laboratory parameters assessed as clinically significant by the investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"SCRs as Defined as Percentage of Subjects With JEV Neutralizing Antibody Titers of PRNT 50 >= 1:10 at Day 56 and Month 7, Measured Using a Validated Plaque Reduction Neutralization Test (PRNT)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"90.6","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs for JEV Neutralizing Antibodies Measured Using a Validated PRNT at Day 56 and Month 7","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"216.18","spread":null},{"groupId":"OG001","value":"340.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.96","spread":null},{"groupId":"OG001","value":"57.12","spread":null}]}]}]},{"type":"SECONDARY","title":"SCRs at Day 56 and Month 7 Stratified According to Dose Groups and Age Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"93.1","spread":null}]}]}]},{"type":"SECONDARY","title":"GMTs at Day 56 and Month 7 Stratified According to Age Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"216.18","spread":null},{"groupId":"OG001","value":"508.03","spread":null},{"groupId":"OG002","value":"295.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.96","spread":null},{"groupId":"OG001","value":"31.96","spread":null},{"groupId":"OG002","value":"60.65","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Tenderness","Muscle Pain","Injection Site Pain","Excessive Fatigue","Nasopharyngitis"]}}}